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ABSTRACT
Introduction: Various studies show that moderate elevation of plasma homocysteine level has been associated with
increased risk for cardiovascular and cerebrovascular disease. Objective: To observe the frequency of increased
homocysteine level in ischemic stroke patients; and its association with other risk factors. Methodology: Observational
pilot study was conducted on a sample of 75 ischemic stroke patients, enrolled regardless of their age, gender and
comorbidities, at Ziauddin university hospital, Karachi. Fasting serum homocysteine, folate and vitamin B12 levels were
measured. Results were interpreted using spss 20.0. Results and Discussion: Mean homocysteine level in our
population was 19.51 (SD: 11.47)micromol/l. It was higher in groups with vitamin B12 and folic acid deficiency,
difference being statistically significant (p=0.013 and 0.017, respectively). Males had greater propensity to
hyperhomocysteinemia; the mean homocysteine value being higher, and the difference, statistically significant
(p=0.010). Other factors that affect homocysteine levels were also evaluated, that is hypertension, increased
cholesterol levels and smoking. There was no significant statistical difference in the homocysteine value between the
groups of patients who had these risk factors and the groups that did not (p=0.747, 0.252 and 0.565, respectively).
Conclusion: It was speculated that hyperhomocysteinemia is an imperative risk factor for stroke.
INTRODUCTION

that although homocysteine-lowering therapies did not
improve the outcome of cardiovascular death, MI and
stroke, but the risk of stroke was reduced by around
25%, after a fair duration of treatment of three years in
persons younger than 70 years with untreated
hyperlipidemia, not receiving antiplatelets and with
hyperhomocysteinemia or folate and vitamin B12
deficiency(10,11). Although the VISP (Vitamin Intervention
for Stroke Prevention) trial showed that high-dose
multivitamin therapy did not help in preventing recurrent
stroke, the control agent used in the trial contained
small doses of vitamin B6, B12, and folic acid, and the
reduction of homocysteine level was less than that
expected in the study. 12 Besides these,
four meta-analyses reporting on the benefit of folic acid
or vitamin B supplementation have been published in
2010(13,14,15,16).

Homocysteine has gained significant attention in the
last decade for its atherogenic properties. Various
studies have shown that moderate elevation of the
plasma level of this metabolite has been associated with
increased risk for cardiovascular and cerebrovascular
disease (1,2,3). Besides causing atherosclerosis, raised
homocysteine levels also increase the risk of vascular
dementia and Alzheimer’s disease (3) Homocysteine
levels may be moderately elevated secondary to
deficiency of enzyme co-factors involved in
homocysteine metabolism (i.e. Vitamin B12, B6
and folate) and genetic polymorphism in
methylenetetrahydrofolatereductase (enzyme involved
in homocysteine metabolism) (3,4). In addition, plasma
levels of homocysteine are influenced by other factors.
Increased levels are associated with high blood
pressure, elevated cholesterol levels,(5) smoking,
increasing age and gender (more prevalent in males) (3,6)
Vascular injury induced by moderately elevated levels of
homocysteine is characterised by intimal thickening,
disruption of elastic lamina, smooth muscle
proliferation, platelet accumulation, and formation of
platelet plugs (7,8). Studies are now being done to
determine whether vitamin therapy reduces the risk of
ischemic stroke and stroke-related disability (9). HOPE-2
(Heart Outcomes Prevention Evaluator 2) study shows
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To observe the frequency of increased homocysteine levels
in patients with ischemic stroke, presenting to our private
tertiary care centre, regardless of their age, gender, race
and social status; and its association with other risk factors.
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RESULTS

B12-deficient had a mean homocysteine level of
28.41(SD: +/- 14.80)Đmol/l, and those with normal
values had a mean level of 17.29(SD: +/- 9.37)Đmol/l.
Statistical difference was significant between the two
groups (p=0.013). Out of the 75 patients, 70 were
hypertensive, with a mean homocysteine level of
19.40(SD: +/-11.52) Đmol/l. The mean homocysteine
value of the 5 non-hypertensive patients was
21.13(SD: +/-11.87) Đmol/l, with no significant
statistical difference between the two groups
(p=0.747). Increased cholesterol level was present in
20 patients and their mean homocysteine value was
16.99(SD: +/-11.99) Đmol/l. In the group of patients
with normal cholesterol level (55 patients), the mean
homocysteine level was 20.44(SD: +/-11.24) Đmol/l;
the statistical difference being not significant between
the two groups (p=0.252). Similarly, no significant
statistical difference was present between the smokers
and non-smokers (p=0.565). There were 14 smokers,
with a mean homocysteine value of 17.91(SD: +/13.60) Đmol/l, and 61 non-smokers, with mean
homocysteine level of 19.88(SD: +/-11.02) Đmol/l.

Out of the 75 enrolled patients, 33(44%) had
moderately elevated homocysteine level, 10(13.3%)
had severely elevated level of more than 30Đmol/l
(Table 1). The mean homocysteine level was 19.52
(SD: +/- 11.47)Đmol/l, with the minimum being 7.02Đ
mol/l and the maximum 50Đmol/l. The mean folate
level was 7.15 (SD: +/- 4.51)ng/ml, with a minimum of
1.12ng/ml and a maximum of 21.50ng/ml. The mean
vitamin B12 level was 432.55 (SD: +/- 293.53) pg/ml;
minimum, 150pg/ml and maximum, 1000pg/ml
Table 1
Homocysteine level (�mol/l)

Valid

Frequency Percent Valid
Percent
Normal <14
32
42.7
42.7
Moderately Elevated >14 33
44.0
44.0

Cumulative
Percent
42.7
86.7

Severely Elevated >30
Total

100.0

10
75

13.3
100.0

13.3
100.0

DISCUSSION

Table 2

Statistics

N

Valid

Missing
Mean
Median
Std. Deviation
Minimum
Maximum

Homocysteine
level
(�mol/l)
75

Folate
level
(ng/ml)
75

Vitamin B12
level (pg/ml)

0
19.5152
16.1500
11.46664
7.02
50.00

0
7.1527
6.0700
4.50741
1.12
21.50

0
432.5467
294.0000
293.53122
150.00
1000.00

The study showed a strong association between
hyperhomocysteinemia and stroke, with 44%of the
patients having moderately elevated levels and 13.3%
having severely elevated levels of more than 30Đmol/l,
making a total of 53.3% of patients. Various studies
have shown that homocysteine levels increase with age
(3,6)
, although our study speculates that there is no
association between hyperhomocysteinemia and
increasing age, as the difference in mean homocysteine
levels was statistically not significant. We also looked
for association between increased homocysteine levels
and gender. As described in different studies previously
(3,6)
, our study also showed a significant difference in
mean homocysteine levels between males and
females. Males had higher propensity to hyperhomocysteinemia than females. Deficiency of enzyme
co-factors involved in homocysteine metabolism (i.e.
Vitamin B12, B6 and folate) and genetic polymorphism
in methylenetetrahydrofolatereductase (enzyme involved
in homocysteine metabolism) are alleged to cause
hyperhomocysteinemia (3,4). In our patients, the patients
who were deficient in vitamin B12 and folic acid had a
greater predilection to hyperhomocysteinemia than
those having normal vitamin B12 and folic acid values,
with a significant statistical difference in the mean
homocysteine value between the two groups. Similarly,
other variables that are individually associated with both
hyperhomocysteinemia and ischemic stroke, were
evaluated, that is hypertension, increased cholesterol

75

Thirty-four of our patients were less than 60 years of
age and the mean homocysteine level in this group was
21.26 (SD: +/-13.55) Đmol/l. In the 41 patients who
were more than and equal to 60 years, the mean
homocysteine level was 18.07(SD: +/- 9.32) Đmol/l.
The difference in the two groups was statistically not
significant (p= 0.250). The mean homocysteine level
of the male patients (41 in number) was 22.44(SD:
+/-13.38)Đmol/ l and that of the female patients was
15.98(SD: +/- 7.37), with a significant statistical
difference between the two (p=0.010). There were 15
patients who had folic acid deficiency and the mean
homocysteine level in this group was 27.49(SD: +/13.83)Đmol/l, compared to the 60 patients with normal
folic acid levels, whose mean homocysteine level was
17.52(SD: +/-9.97)Đmol/l. The difference among the
two groups was statistically significant with a p-value of
0.017. 15 of the patients who were vitamin
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Table 3
Variables

Subgroups

Frequency

Age groups

Age less than 60
Age more than and
equal to 60
Male
Female
Deﬁciency
Normal level
Deﬁciency
Normal level
Present
Absent
Present
Absent
Smoker
Non-smoker

Gender
Folic acid
Vitamin B12
Hypertension
Increased
Cholesterol
Smoking

Standard
Deviation

p- value

34
41

Mean
Homocysteine
level
21.26
18.07

+/-13.55
+/-9.32

0.250

41
34
15
60
15
60
70
5
20

22.44
15.98
27.49
17.52
28.41
17.29
19.40
21.13
16.99

+/-13.38
+/-7.37
+/-13.83
+/-9.97
+/-14.80
+/-9.37
+/-11.52
+/-11.87
+/-11.99

0.010

55
14
61

20.44
17.91
19.88

+/-11.24
+/-13.60
+/-11.02

0.013
0.747
0.252
0.565

rather cost-effective, it should be considered for use in
these patients (though with caution in patients with
renal failure or decreased glomerular filtration rate, in
whom more active forms i.e. methylcobolamin and
tetrahydrofolate are recommended).17

levels (5) and smoking (3,6). The group of patients that
were non-hypertensive also had an elevated mean
homocysteine value and the difference in the mean
level between the hypertensive and non-hypertensive
group was statistically not significant. In the same way,
there was no significant statistical difference in the
mean homocysteine value between the group of
patients having increased cholesterol levels and that
with normal cholesterol levels. So, it can be speculated
that increased cholesterol levels do not directly relate to
hyperhomocysteinemia. Non-smokers had a higher
mean homocysteine value, compared to the smokers,
the difference being statistically non-significant,
showing that there is no association between this
variable and hyperhomocysteinemia.
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